Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population

Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population The Framingham Heart Study ORIGINAL INVESTIGATION Donald M. Lloyd-Jones, MD; Christopher J. O Donnell, MD, MPH; Ralph B. D Agostino, PhD; Joseph Massaro, PhD; Halit Silbershatz, PhD; Peter W. F. Wilson, MD Background: Four large trials have shown cholesterolreduction therapy to be effective for primary prevention of coronary heart disease (CHD). Methods: To determine the generalizability of these trials to a community-based sample, we compared the total cholesterol and high-density lipoprotein cholesterol (HDL-C) distributions of patients in the 4 trials with those of Framingham Heart Study subjects. Lipid profiles that have not been studied were identified. Twelve-year rates of incident CHD were compared between subjects who met eligibility criteria and those who did not. Results: The Framingham sample included 2498 men and 287 women aged 3 to 74 years. Among Framingham men, 23.4% to 42.% met eligibility criteria for each of the 4 trials based on their lipid levels; 6.2% met eligibility criteria for at least 1 trial. For the 1 trial that included women, 2.2% of Framingham women met eligibility criteria. In general, subjects with desirable total cholesterol levels and lower HDL-C levels and subjects with average total cholesterol levels and average to higher HDL-C levels have not been included in these trials. Among subjects who developed incident CHD during follow-up, 25.1% of men and 66.2% of women would not have been eligible for any trial. Most ineligible subjects who developed CHD had isolated hypertriglyceridemia ( 2.25 mmol/l [ 2 mg/dl]). Conclusions: In our sample, 4% of men and 8% of women had lipid profiles that have not been studied in large trials to date. We observed a large number of CHD events in ineligible subjects in whom hypertriglyceridemia was common. Further studies are needed to define the role of lipid-lowering therapy vs other strategies for primary prevention in the general population. Arch Intern Med. 21;161:949-954 From the Framingham Heart Study, National Heart, Lung and Blood Institute, the National Institutes of Health, Bethesda, Md (Drs Lloyd-Jones, O Donnell, and Wilson); the Cardiology Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School (Drs Lloyd-Jones and O Donnell), the Departments of Mathematics and Statistics, Boston University (Drs D Agostino and Silbershatz), and Epidemiology and Biostatistics, Boston University School of Public Health (Dr Massaro), Boston, Mass. DYSLIPIDEMIA is a wellestablished risk factor for coronary heart disease (CHD). However, the risk associated with increasing total cholesterol and decreasing highdensity lipoprotein cholesterol (HDL-C) levels is continuous and graded; there are no clear threshold values to discriminate subjects who will develop CHD from those who will not. For example, when examining univariate distributions of lipid parameters, there is considerable overlap between the total cholesterol distribution of men with and without prevalent CHD. 1 Similarly, there is considerable overlap in the distribution of HDL-C for men with and without CHD. 1 A simple method of graphically depicting the overlap of total cholesterol and HDL-C distributions to compare those with and without CHD is to plot bivariate ellipsoids representing the means±2 SDs of the 2 parameters simultaneously (Figure 1). To date, there have been 4 large randomized placebo-controlled trials of cholesterol reduction aimed at primary prevention of CHD: the Lipid Research Clinics Coronary Primary Prevention Trial (LRC- CPPT), 2 the Helsinki Heart Study (HHS), 3 the West of Scotland Coronary Prevention Study (WOSCOPS), 4 and the Air Force/ Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). 5 These trials have demonstrated significant 19% to For editorial comment see page 922 37% reductions in the risk of first coronary events and/or mortality with cholesterol-lowering therapy compared with placebo. Such results provide encouraging evidence that more widespread use of lipidlowering therapy for primary prevention could substantially reduce the extensive mortality and disability associated with CHD. However, the inclusion criteria for these trials have generally specified only perceived high-risk lipid profiles, and only AFCAPS/TexCAPS included women. 949

PARTICIPANTS AND METHODS STUDY SAMPLE The Framingham Heart Study was established in 1948 when 529 residents of Framingham, Mass, aged 28 to 62 years, were enrolled to evaluate potential risk factors for CHD. 6,7 Members of this cohort have received follow-up evaluations every 2 years with medical history reviews and physical examinations as well as selected laboratory tests. In 1971, 5124 additional subjects (offspring of original cohort subjects and their spouses) were enrolled in the Framingham Offspring Study. 8,9 These participants have received follow-up evaluations approximately every 4 years. All examinations and procedures have been approved by the institutional review board of Boston University School of Medicine, Boston, Mass. The current study sample included original cohort participants in examination cycle 12 (1971-1974), and offspring cohort participants in examination cycle 1 (1971-1975). To determine the applicability of the 4 cholesterol-lowering primary prevention trials to a primary prevention population, we restricted our analyses to members of the original and offspring cohorts who were between ages 3 and 74 years and had fasting lipids measured at the index examination. Further, we excluded subjects with prevalent CHD (defined as history of definite angina pectoris, coronary insufficiency, or myocardial infarction). FASTING LIPID MEASUREMENTS Blood was drawn at the index examination after an overnight fast, and ethylenediaminetetraacetic acid plasma was used for all cholesterol and triglyceride measurements. Cholesterol levels were determined according to the Abell-Kendall technique, 1 and HDL-C levels were measured after precipitation of very low-density lipoproteins and low-density lipoproteins (LDLs) with heparin magnesium following the Lipid Research Clinics Program protocol. 11 When triglyceride levels were lower than 4.52 mmol/l (4 mg/dl), the concentration of LDL cholesterol (LDL-C) was estimated indirectly using the Friedewald formula 12 ; for triglyceride levels at 4.52 mmol/l (4 mg/dl) or higher, the concentration of LDL-C was estimated directly after ultracentrifugation of plasma and measurement of cholesterol in the bottom fraction when plasma density was less than 1.6. 13 For the purposes of this study, hypertriglyceridemia was defined as a triglyceride level higher than 2.25 mmol/l (2 mg/dl), and low HDL-C was defined as an HDL-C level lower than.9 mmol/l (35 mg/dl). STATISTICAL ANALYSIS We compared the lipid levels of the Framingham Heart Study sample with the published entry lipid ranges of participants in each of the 4 trials to determine the number and proportion of Framingham subjects who met eligibility criteria for each study. Bivariate ellipsoids were constructed separately for men and women using the mean±2 SDs to represent the total cholesterol and HDL-C distributions of the study sample. The entry lipid ranges of the trials were overlaid on the bivariate ellipsoids of the Framingham sample (Figure 2) to graphically display the relative proportions of eligible Framingham subjects. Subjects were observed for 12 years for incident CHD events (defined as coronary insufficiency, myocardial infarction, or coronary death) using previously published criteria. 14 Surveillance for CHD consisted of regular examinations at the Framingham Heart Study clinic, Framingham, Mass, and review of medical records from outside physician office visits and hospitalizations. We calculated the rates of incident CHD over 12 years for all Framingham Heart Study subjects, subjects who met eligibility criteria for each of the trials, and subjects who did not meet eligibility criteria for any of the trials. To characterize the lipid profiles that merit further study, we also examined the trial eligibility and lipid levels of subjects who had incident CHD events during follow-up. Therefore, the applicability of the results of these trials to a general population remains unknown. Furthermore, the unstudied lipid profiles that merit further examination in clinical trials have not been fully elucidated. In our current study, we determine the proportion of subjects from a community-based sample who met or did not meet eligibility criteria for the 4 trials based on their lipid levels. Using bivariate ellipsoids, we depict graphically the lipid profiles that have not yet been studied in these trials. To identify subgroups of patients who may be at high risk for CHD but whose lipid profiles have not been included in the trials to date, we also determined the proportion of incident CHD events that occurred in subjects who did not meet eligibility criteria. RESULTS The Framingham sample included 2498 men and 287 women (aged 3-74 years) from Framingham who were free of prevalent CHD and had fasting lipid levels drawn at the index examination. The baseline characteristics of the Framingham sample and the participants in each of the 4 trials are given in Table 1. Three of the trials studied participants with mean pretreatment total cholesterol levels substantially higher than those observed in the Framingham sample. The AFCAPS/TexCAPS participants had similar total cholesterol levels but lower HDL-C levels compared with the Framingham sample. The prevalences of nonlipid CHD risk factors varied markedly across the 4 trial populations. ELIGIBILITY FOR TRIALS The bivariate ellipsoids for the total cholesterol and HDL-C distributions in the Framingham sample are shown in Figure 2 and Figure 3 for men and women, respectively. The overlaid rectangles represent the entry lipid levels for each of the 4 trials. Framingham subjects whose lipid levels met eligibility criteria for a given study would fall within the area covered by the rectangle for that study. As defined by their entry criteria, the trials have tended to include subjects with high total cholesterol levels and 95

HDL-C, mmol/l (mg/dl) 2.6 (1) 2.1 (8) 1.6 (6) 1. (4).5 (2) 2.6 (1) Prevalent CHD No CHD 5.2 (2) 7.8 (3) Total Cholesterol, mmol/l (mg/dl) 1.3 (4) Figure 1. Bivariate ellipsoids showing the mean±2 SDs of the total and high-density lipoprotein cholesterol (HDL-C) levels of men with (solid line) and without (broken line) prevalent coronary heart disease (CHD) in the Framingham Heart Study (data from Wilson et al 1 ). The center point of each ellipsoid represents the mean total cholesterol and HDL-C value for that group. The horizontal axes of the ellipsoids include the mean±2 SDs of the total cholesterol level; the vertical axes of the ellipsoids include the mean±2 SDs of the HDL-C value. Note the considerable overlap of the 2 ellipsoids for those with and without prevalent CHD. HDL-C, mmol/l (mg/dl) 2.6 (1) 2.1 (8) 1.6 (6) 1. (4).5 (2) 2.6 (1) Framingham Heart Study Helsinki Heart Study Lipid Research Clinics Coronary Prevention Trial 5.2 (2) 7.8 (3) Total Cholesterol, mmol/l (mg/dl) West of Scotland Coronary Prevention Study Air Force/Texas Coronary Atherosclerosis Prevention Study Figure 2. Bivariate ellipsoid representing the mean±2 SDs of the total cholesterol and high-density lipoprotein cholesterol (HDL-C) levels of the 2498 Framingham men in the study sample, with rectangular overlays representing the entry lipid levels of the 4 large randomized cholesterol-lowering primary prevention trials. 1.3 (4) Table 1. Baseline Characteristics of Framingham Heart Study Participants and Patients in the 4 Large Randomized Cholesterol-Lowering Primary Prevention Trials* Men Women Characteristic FHS LRC-CPPT HHS WOSCOPS AFCAPS/TexCAPS FHS AFCAPS/TexCAPS Mean age (range), y 47 (3-74) 47 (35-59) 47 (4-55) 55 (45-64) 58 (45-73) 49 (3-74) 58 (55-73) Mean ± SD total 5.5 ± 1. 7.2 ±.9 7.5 ±.8 7. ±.6 5.7 ±.5 5.6 ± 1.2 5.7 ±.5 cholesterol, (213 ± 4) (279 ± 35) (289 ± 32) (272 ± 23) (221 ± 21) (218 ± 45) (222 ± 21) mmol/l (mg/dl) Mean ± SD HDL-C, 1.2 ±.3 1.2 ±.3 1.2 ±.3 1.1 ±.3.9 ±.1 1.5 ±.4 1. ±.1 mmol/l (mg/dl) (45 ± 12) (45 ± 1) (47 ± 11) (44 ± 1) (36±5) (58 ± 16) (4±5) Current smoker, % 4.5 N/A 36.2 44. 12.4 37.6 12.4 Diabetes mellitus, % 5.2 Excluded 2.6 1. 3.6 3.9 3.6 Hypertension 35.8 Excluded 14. 15.7 21.9 29.8 21.9 *FHS indicates Framingham Heart Study; LRC-CPPT, Lipid Research Clinics Coronary Primary Prevention Trial; HHS, Helsinki Heart Study; WOSCOPS, West of Scotland Coronary Prevention Study; AFCAPS/TexCAPS, Air Force Texas Coronary Atherosclerosis Prevention Study; HDL-C, high-density lipoprotein cholesterol; and N/A, not applicable. Women were only included in FHS and AFCAPS/TexCAPS. Hypertension was defined as blood pressure 14/ 9 mm Hg. Blood pressure 17/ 1 or diastolic 15 mm Hg or on treatment. Self-reported history of hypertension or receiving treatment. Not reported separately for men and women. generally those with low HDL-C levels. As shown in Figure 2, men with desirable total cholesterol levels and lower HDL-C levels (lower left quadrant of the bivariate ellipsoid), and men with average total cholesterol levels and average to higher HDL-C levels (upper left quadrant of the bivariate ellipsoid) have not been included in these trials. Table 2 gives the number and percentage of Framingham men and women who fell into the area covered by each of the studies. In men, the percentages ranged from a low of 23.4% who had lipid levels eligible for LRC-CPPT, to a high of 42.% who had levels eligible for AFCAPS/TexCAPS. In the aggregate, 6.2% of the men fell into an area covered by at least 1 of the studies, leaving 39.8% who would not have been eligible for any of the studies. Using AFCAPS/TexCAPS criteria, only 2.2% of Framingham women had lipid levels that met eligibility criteria for this trial, whereas 79.8% had lipid levels that did not. OUTCOMES During 12 years of follow-up, 275 men (11.%) and 136 women (4.7%) developed CHD. The rates of incident CHD were 17.1%, 14.9%, 15.9%, and 12.9% in men eligible for LRC-CPPT, HHS, WOSCOPS, and AFCAPS/ TexCAPS, respectively. Among the men eligible for at least 1 of the trials, the rate of 12-year incident CHD was 13.7%; in women eligible for AFCAPS/TexCAPS it was 7.9%. The rates of 12-year incident CHD among men or women ineligible for all trials were half the rates observed in subjects eligible for at least 1 trial (Figure 4). 951

HDL-C, mmol/l (mg/dl) 2.6 (1) 2.1 (8) 1.6 (6) 1. (4).5 (2) Framingham Heart Study Air Force/Texas Coronary Atherosclerosis Prevention Study 12-Year Incident CHD per 1 Subjects 16 12 8 4 137 Eligible 69 Ineligible 79 Eligible 39 Ineligible 2.6 (1) 5.2 (2) 7.8 (3) Total Cholesterol, mmol/l (mg/dl) 1.3 (4) Figure 3. Bivariate ellipsoid representing the mean±2 SDs of the total and high-density lipoprotein cholesterol (HDL-C) levels of the 287 Framingham women in the study sample, with the rectangular overlay representing the entry lipid levels of Air Force/Texas Coronary Atherosclerosis Prevention Study (the only trial to include women). Table 2. Framingham Subjects With Lipid Profiles Eligible for the 4 Large Randomized Cholesterol-Lowering Primary Prevention Trials* Trial Men Women FHS 2498 (1.) 287 (1.) LRC-CPPT 584 (23.4)... HHS 818 (32.7)... WOSCOPS 7 (8.)... AFCAPS/TexCAPS 149 (42.) 58 (2.2) Eligible for at least 1 trial 153 (6.2)... *Values are number (percentage) of subjects. FHS indicates Framingham Heart Study; LRC-CPPT, Lipid Research Clinics Coronary Primary Prevention Trial; HHS, Helsinki Heart Study; WOSCOPS, West of Scotland Coronary Prevention Study; AFCAPS/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study; and ellipses, not included in trial. Men Of the 275 men with incident CHD, 69 (25.1%) would not have been eligible for any of the trials. Of these 69, most (n=62) had hypertriglyceridemia, representing 22.5% of all men with incident CHD. Among the 62 men with hypertriglyceridemia, 43 had isolated hypertriglyceridemia, and 19 had hypertriglyceridemia with associated low levels of HDL-C, representing 15.6% and 6.9%, respectively, of all men with incident CHD. Only 33.8% of the 136 women with incident CHD met eligibility criteria for AFCAPS/TexCAPS, whereas most (n=9 [66.2%]) did not. Of these 9 women, 83 (61.% of women with incident CHD) had hypertriglyceridemia, and only 6 (4.4%) had associated low levels of HDL-C. Since diabetes may have confounded the relationship between hypertriglyceridemia and incident CHD, we examined whether the prevalence of diabetes was higher among subjects who developed CHD and were ineligible for the trials compared with those who met eligibility criteria. Among men who developed CHD, the prevalence of diabetes was 15.9% for those who were ineligible compared with 1.2% for those who were eligible (P=.2). Among women who developed CHD, the prevalence of diabetes was 2.% for those who were ineligible compared with 1.8% for those who were eligible (P=.23). COMMENT Women Figure 4. Rates of 12-year incident coronary heart disease (CHD) among men and women from the Framingham sample who met eligibility criteria for at least 1 trial compared with those who did not meet criteria for any of the trials. In our community-based population of adults without CHD aged 3 to 74 years, 4% of men and 8% of women had lipid profiles that did not meet eligibility criteria for inclusion in the large primary prevention trials published to date. Men who have not been included in trials include those with desirable total cholesterol and low HDL-C levels, and those with average total cholesterol and average to higher HDL-C levels. Randomized trial data remain sparse for women across a wide range of lipid profiles (other than those in AFCAPS/TexCAPS). IMPLICATIONS FOR CLINICAL PRACTICE AND RESEARCH Rates of incident CHD during follow-up were half as great among subjects who did not meet eligibility criteria for the trials compared with those who were eligible. This finding validates the inclusion criteria of the trials in that higher-risk individuals were selected for cholesterollowering intervention. Nonetheless, a substantial proportion of first CHD events (25% in men and 66% in women) occurred among subjects with lipid profiles that have not been studied. Most ineligible subjects with incident CHD had hypertriglyceridemia with or without low HDL-C levels. Therefore, further primary prevention trials targeting hypertriglyceridemia and low HDL-C levels seem warranted. In addition, further epidemiologic studies examining the population-attributable risk associated with hypertriglyceridemia would be useful. With the current paucity of clinical trial data for primary prevention in women, clinicians may be using the published primary prevention trial results for men to inform treatment decisions for their female patients. However, because of the different endocrinologic and cardiovascular milieu present in women, extrapolation of results from male trial participants may be misleading. This may be true particularly for premenopausal 952

women, who generally have a very low risk of incident CHD and may be much less likely to benefit from primary prevention than higher-risk subgroups. Women may currently be receiving drug therapy with little chance of benefit but some risk of adverse toxic effects. Further trials of the efficacy and safety of lipid-lowering therapy for primary prevention of CHD in women are therefore warranted. IMPLICATIONS FOR PUBLIC HEALTH The findings of this study have implications in terms of the cost-effectiveness of primary prevention with lipidlowering agents. Currently, medical therapy of dyslipidemia has been firmly established as cost-effective for secondary prevention of CHD. Data from the Scandinavian Simvastatin Survival Study (4S) indicate that 13 patients with CHD would need to be treated for 5 years to prevent 1 recurrent major coronary event. 15 In considering the cost-effectiveness of an intervention, the concept of cost per year of life gained is typically used. Interventions that cost less than $2 per year of life gained are generally considered to be very costeffective, and those that cost less than $4 have been recommended by some authors, whereas those that cost more than $75 are generally considered not cost-effective. 16 From 4S, the direct costs per year of life gained using simvastatin for secondary prevention ranged from $38 for 7-year-old men with a total cholesterol level of 8. mmol/l (39 mg/dl) to $274 for 35-year-old women with a total cholesterol level of 5.5 mmol/l (213 mg/dl). When indirect costs were included, the costs per year of life gained ranged from a net savings in 35-year-old patients to a cost of $133 for 7-year-old women with a cholesterol level of 5.5 mmol/l (213 mg/dl). 17 Such data have led to the widespread acceptance of medical therapy for secondary prevention of CHD in patients with hypercholesterolemia. In contrast, the role of medical therapy of dyslipidemia for the primary prevention of CHD remains controversial because of the potential costs involved in treating large segments of the population. From the 4 primary prevention trials, a range of approximately 4 to 75 patients would need to be treated for 5 years to prevent a single coronary event. As previously noted, these studies have selected patients with relatively high-risk lipid profiles that reflect a fairly small proportion of the general population. The study sample in AFCAPS/ TexCAPS was most representative of the general population in that it was a healthy group of men and women with average total cholesterol and LDL-C values but below average HDL-C levels. In AFCAPS/TexCAPS, it was estimated that 53 patients would need to be treated with lovastatin for 5 years to prevent a single acute coronary event (including unstable angina and myocardial infarction). In the past decade, the introduction and widespread use of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (the statin compounds) have clearly provided a major therapeutic advance in the treatment of hypercholesterolemia. Indeed, WOSCOPS and AFCAPS/TexCAPS observed greater relative reductions in coronary events with statins than did LRC- CPPT or HHS with cholestyramine and gemfibrozil, respectively, despite the fact that the latter 2 trials had higher baseline total cholesterol levels. However, statins are also significantly more costly than the older medications. The cost-effectiveness of cholesterol-lowering therapy for primary prevention has therefore been questioned. Estimates of the cost-effectiveness of medical therapy for primary prevention vary widely, depending on the risk profile of the population studied. 16,18 In one study by Goldman et al, 19 therapy with statins was not cost-effective for any subgroup of women, and only men with multiple risk factors (eg, combined obesity, smoking, and hypertension) had costs per year less than $4. In another analysis using Framingham risk equations, Hamilton and colleagues 2 adjusted for the additional benefit of HDL level elevation seen with lovastatin therapy. They calculated costs of $28 to $44 per year of life gained for low-risk men aged 4 to 6 years and low-risk women aged 5 to 7 years. For higher-risk men, the costs ranged from $13 to $33. 18 Thus, the challenge for clinicians and policy makers is to identify higher-risk patients for whom medical therapy will be more cost-effective. Selection of highrisk patients using multivariate risk score 21 or global risk assessment strategies 22,23 is likely to improve the clinical effectiveness and cost-effectiveness of antihyperlipidemia drugs. As CHD incidence was approximately half as great among those who did not meet eligibility criteria compared with those who were eligible, the cost-effectiveness of treating dyslipidemia in the large subgroup of ineligible patients may be poor. Similarly, the number of subjects who need to be treated to prevent 1 CHD event in this subgroup likely exceeds the value of 53 observed in AFCAPS/TexCAPS. Nonetheless, the high proportion of incident CHD events that occurred in the ineligible subgroup should be of concern to policy makers and clinicians alike. Therefore, other strategies including public health and individual measures aimed at aggressive dietary management and control of other coronary risk factors should also be considered in the treatment of patients with these unstudied lipid abnormalities. Such an approach may be preferable given that hypertriglyceridemia and low HDL-C levels are often markers of other metabolic risk factors for CHD, including hyperinsulinemia, central obesity, and hypertension. It should be noted that none of the groups of Framingham subjects who met eligibility criteria for any of the trials had 1-year rates of CHD that exceeded the level of 2%, which has recently been recommended as a threshold for screening and treatment of coronary risk factors by the joint task force from the european societies of cardiology, atherosclerosis, and hypertension. 23 Therefore, further study is needed of risk-stratification techniques designed to identify higher-risk patients among the ineligible subgroup. Such techniques might involve the routine incorporation of triglyceride and HDL-C data into risk assessment and might indicate further strategies to provide optimal risk reduction. 953

POTENTIAL LIMITATIONS This study has several potential limitations. First, the original and offspring cohorts of the Framingham Heart Study are composed almost exclusively of white individuals. However, data from the NHANES (National Health and Nutrition Examination Study) surveys from the 197s through the 199s indicate that in the United States, mean cholesterol values vary by less than 5 points across different ethnic groups for men and women, 24(p191) and the proportions of individuals with hypercholesterolemia are remarkably similar across ethnicities. 25 Therefore, our findings would likely apply to other ethnicities as well. Second, the Framingham sample represents the experience of a single municipality. There are known regional variations in both lipid values and rates of incident CHD within the United States. However, the risk profile of the Framingham subjects used in this report is quite similar to concurrent national profiles with regard to prevalence of smoking, diabetes, and hypertension, as well as hypercholesterolemia. 24 It should be noted that the mean HDL-C level for women in our Framingham sample was 1.5 mmol/l (58 mg/dl), slightly higher than the mean HDL-C level of 1.4 mmol/l (54 mg/dl) for white women in this age range from the NHANES II sample. 26 Finally, to allow examination of follow-up events, we used data from Framingham subjects seen in the 197s and observed into the 198s, so incident rates of CHD from the Framingham sample may not be representative of a current sample. These data are likely to be more accurate than NHANES follow-up data, however, because national data must rely on death certificates, which can be unreliable when used to diagnose CHD. 27 CONCLUSIONS In conclusion, a substantial proportion of CHD events occurs in individuals with lipid profiles that have not been included in large primary prevention trials to date. Further research seems warranted in men with hypertriglyceridemia and in women with all lipid profiles. Given that the perceived high-risk lipid profiles have been studied, the role of lipid-lowering therapy vs other strategies to reduce risk in the unstudied groups is unclear. Accepted for publication September 9, 2. This research was supported by the National Institutes of Health National Heart, Lung, and Blood Institute, Bethesda Md, contract N1-HC-3838 (Drs Lloyd-Jones, O Donnell, and Wilson). Reprints: Peter W. F. Wilson, MD, Framingham Heart Study, 5 Thurber St, Framingham, MA 172 (e-mail: peter@fram.nhlbi.nih.gov). REFERENCES 1. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol. 198;46:649-654. 2. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364. 3. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987; 317:1237-1245. 4. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:131-137. 5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622. 6. Gordon T, Moore FE, Shurtleff D, Dawber TR. Some methodologic problems in the long-term study of cardiovascular disease: observations on the Framingham Study. J Chronic Dis. 1959;1:186-26. 7. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham Study. Ann N Y Acad Sci. 1963;17:539-556. 8. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;11:281-29. 9. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study: design and preliminary data. Prev Med. 1975;4:518-525. 1. Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem. 1952;195:357-366. 11. National Institutes of Health. Lipid Research Clinics Program: Manual of Laboratory Operations. Bethesda, Md: National Institutes of Health; 1974. 12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-52. 13. US Department of Health and Human Services. Manual of Laboratory Operations: Lipid Research Clinics Program, Lipid and Lipoprotein Analysis. Bethesda, Md: National Institutes of Health, US Dept of Health and Human Services; 1982. 14. Abbott RD, McGee DL. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease, Section 37: The Probability of Developing Certain Cardiovascular Diseases in Eight Years at Specified Values of Some Characteristics. Bethesda, Md: National Heart, Lung, and Blood Institute; 1987. 15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389. 16. Goldman L, Garber AM, Grover SA, Hlatky MA. Task Force 6: cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol. 1996;27: 12-13. 17. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H, for the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336:332-336. 18. Jacobson TA, Schein JR, Williamson A, Ballantyne CM. Maximizing the costeffectiveness of lipid-lowering therapy. Arch Intern Med. 1998;158:1977-1989. 19. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG- CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991;265:1145-1151. 2. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDL-C. JAMA. 1995;273:132-138. 21. Wilson PWF, D Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97:1837-1847. 22. Fuster V, Pearson TA. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol. 1996;27:957-147. 23. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J. 1998;19:1434-153. 24. National Center for Health Statistics. Health, United States, 1996-97. Hyattsville, Md: US Public Health Service; 1997. 25. Sempos CT, Cleeman JI, Carroll MD, et al. Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA. 1993; 269:39-314. 26. Linn S, Fulwood R, Rifkind B, et al. High density lipoprotein cholesterol levels among US adults by selected demographic and socioeconomic variables. Am J Epidemiol. 1989;129:281-294. 27. Lloyd-Jones DM, Martin DO, Larson MG, Levy D. Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med. 1998; 129:12-126. 954